We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of 37 cents, which surpassed the Zacks Consensus Estimate by 68.18%. CareDx’s earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 85.66%.
CDNA’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $122.4 million, indicating an increase of 22.3% from the year-ago figure.
The Zacks Consensus Estimate for EPS is pinned at 24 cents, implying a decline of 14.3% from the year-ago figure.
Estimate Revision Trend Ahead of CDNA’s Q3 Earnings
Estimates for third-quarter earnings have remained unchanged in the past 60 days.
Here’s a brief snapshot of the pet healthcare innovator’s performance leading up to the announcement.
Key Drivers of CDNA’s Q3 Performance
The company is likely to have sustained its growth momentum in the third quarter of 2026, supported by higher Testing Services revenues and continued expansion of Patient and Digital Solutions revenues. Strong demand across transplant programs, favorable reimbursement dynamics and increases in testing activity across both surveillance and for-cause settings are expected to have boosted the third-quarter top line.
Several strategic developments are also expected to have supported CareDx’s revenue growth. In line with this, the divestiture of the Lab Products business to Eurobio Scientific must have allowed the company to focus on its core molecular diagnostics operations, while the acquisition of Naveris might have expanded its presence in specialty oncology through the NavDx test for molecular surveillance of HPV-driven cancers.
Meanwhile, the finalization of Medicare coverage for AlloSure and AlloMap strengthened reimbursement visibility for transplant surveillance testing, while AlloHeme’s clinical validation progress and planned CLIA readiness in 2026 supported CareDx’s expansion into cell therapy diagnostics, with commercial launch targeted for 2027.
CDNA’s strong financial position and operational capabilities are likely to have supported continued business expansion. In the second quarter of 2026, cash collections increased 49% year over year to $136 million, while operating cash flow reached $31 million. The company ended the quarter with $374 million in cash and cash equivalents and no debt, providing financial flexibility to support its growth initiatives. Approximately 90% of transplant test volume was electronically connected through integrated electronic medical records or CareDx's care portal, supporting workflow efficiency. We expect these trends to have persisted in the third quarter as well.
On the flip side, CareDx’s third-quarter performance may have faced pressure from a challenging sequential comparison, as sizable out-of-period revenues had boosted second-quarter testing services revenues and gross margins. Per management, out-of-period revenues are expected to decline to $8 million in the third quarter. Moreover, additional investments to expand CareDx’s specialty oncology business could temporarily weigh on EBITDA margins as the company balances growth initiatives with near-term profitability.
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: CareDx has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed in the other three, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #3 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.
View the Zacks #1 Rank List
Image: Bigstock
CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus
Key Takeaways
CareDx, Inc. (CDNA - Free Report) is expected to release third-quarter 2026 results soon.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of 37 cents, which surpassed the Zacks Consensus Estimate by 68.18%. CareDx’s earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 85.66%.
CDNA’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $122.4 million, indicating an increase of 22.3% from the year-ago figure.
The Zacks Consensus Estimate for EPS is pinned at 24 cents, implying a decline of 14.3% from the year-ago figure.
Estimate Revision Trend Ahead of CDNA’s Q3 Earnings
Estimates for third-quarter earnings have remained unchanged in the past 60 days.
Here’s a brief snapshot of the pet healthcare innovator’s performance leading up to the announcement.
Key Drivers of CDNA’s Q3 Performance
The company is likely to have sustained its growth momentum in the third quarter of 2026, supported by higher Testing Services revenues and continued expansion of Patient and Digital Solutions revenues. Strong demand across transplant programs, favorable reimbursement dynamics and increases in testing activity across both surveillance and for-cause settings are expected to have boosted the third-quarter top line.
Several strategic developments are also expected to have supported CareDx’s revenue growth. In line with this, the divestiture of the Lab Products business to Eurobio Scientific must have allowed the company to focus on its core molecular diagnostics operations, while the acquisition of Naveris might have expanded its presence in specialty oncology through the NavDx test for molecular surveillance of HPV-driven cancers.
Meanwhile, the finalization of Medicare coverage for AlloSure and AlloMap strengthened reimbursement visibility for transplant surveillance testing, while AlloHeme’s clinical validation progress and planned CLIA readiness in 2026 supported CareDx’s expansion into cell therapy diagnostics, with commercial launch targeted for 2027.
CDNA’s strong financial position and operational capabilities are likely to have supported continued business expansion. In the second quarter of 2026, cash collections increased 49% year over year to $136 million, while operating cash flow reached $31 million. The company ended the quarter with $374 million in cash and cash equivalents and no debt, providing financial flexibility to support its growth initiatives. Approximately 90% of transplant test volume was electronically connected through integrated electronic medical records or CareDx's care portal, supporting workflow efficiency. We expect these trends to have persisted in the third quarter as well.
On the flip side, CareDx’s third-quarter performance may have faced pressure from a challenging sequential comparison, as sizable out-of-period revenues had boosted second-quarter testing services revenues and gross margins. Per management, out-of-period revenues are expected to decline to $8 million in the third quarter. Moreover, additional investments to expand CareDx’s specialty oncology business could temporarily weigh on EBITDA margins as the company balances growth initiatives with near-term profitability.
CareDx, Inc. Price and EPS Surprise
CareDx, Inc. price-eps-surprise | CareDx, Inc. Quote
What Our Model Says About CDNA
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: CareDx has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed in the other three, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #3 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.